Apocynin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Apocynin
Accession Number
DB12618
Type
Small Molecule
Groups
Investigational
Description

Acetovanillone has been used in trials studying the treatment of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.

Structure
Thumb
Synonyms
  • Acetovanillone
Categories
UNII
B6J7B9UDTR
CAS number
498-02-2
Weight
Average: 166.1739
Monoisotopic: 166.062994186
Chemical Formula
C9H10O3
InChI Key
DFYRUELUNQRZTB-UHFFFAOYSA-N
InChI
InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3
IUPAC Name
1-(4-hydroxy-3-methoxyphenyl)ethan-1-one
SMILES
COC1=C(O)C=CC(=C1)C(C)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Apocynin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with 5-androstenedione.Experimental, Illicit
AbciximabApocynin may increase the anticoagulant activities of Abciximab.Approved
AcebutololApocynin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Apocynin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolApocynin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Apocynin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Apocynin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Alendronic acid.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Alminoprofen.Experimental
AlprenololApocynin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Apocynin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Amcinonide.Approved
AmilorideApocynin may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneApocynin may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodApocynin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Apocynin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Apocynin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Apocynin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Apocynin.Investigational
Antithrombin III humanApocynin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApocynin may increase the anticoagulant activities of Apixaban.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Apocynin.Approved, Investigational
ArdeparinApocynin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanApocynin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololApocynin may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineApocynin may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Apocynin is combined with Atamestane.Investigational
AtenololApocynin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Apocynin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Apocynin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Apocynin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apocynin.Approved, Investigational
BecaplerminApocynin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololApocynin may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Apocynin is combined with Bendazac.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Apocynin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Apocynin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Apocynin is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Apocynin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Betamethasone.Approved, Vet Approved
BetaxololApocynin may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BevantololApocynin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Apocynin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Apocynin.Approved, Investigational
BisoprololApocynin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinApocynin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololApocynin may decrease the antihypertensive activities of Bopindolol.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Apocynin.Investigational
BucindololApocynin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Budesonide.Approved
BufuralolApocynin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Bumadizone.Experimental
BupranololApocynin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Apocynin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Apocynin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Apocynin is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Apocynin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Apocynin.Approved
CarteololApocynin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolApocynin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Apocynin.Experimental
CeliprololApocynin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinApocynin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Apocynin.Approved, Investigational, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Cilazapril.Approved
Citric AcidApocynin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Clocortolone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Apocynin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Apocynin.Vet Approved
CloranololApocynin may decrease the antihypertensive activities of Cloranolol.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Apocynin.Approved, Investigational
Dabigatran etexilateApocynin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinApocynin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidApocynin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanApocynin may increase the anticoagulant activities of Darexaban.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Apocynin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Delapril.Experimental
DesipramineApocynin may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinApocynin may increase the anticoagulant activities of Desirudin.Approved
DesonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Apocynin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Apocynin.Approved, Investigational
DextranApocynin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dibotermin alfaThe risk or severity of adverse effects can be increased when Apocynin is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Apocynin.Approved, Vet Approved
DicoumarolApocynin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Apocynin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Apocynin is combined with Difluprednate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Apocynin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Apocynin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Apocynin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Apocynin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Apocynin.Investigational
Edetic AcidApocynin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanApocynin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Apocynin is combined with Enalaprilat.Approved
EnoxaparinApocynin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Apocynin.Experimental
EpanololApocynin may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Apocynin.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Apocynin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apocynin.Approved
EquileninThe risk or severity of adverse effects can be increased when Apocynin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Apocynin is combined with Equilin.Approved
EsatenololApocynin may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololApocynin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Apocynin is combined with Estrone sulfate.Approved
EthenzamideThe risk or severity of adverse effects can be increased when Apocynin is combined with Ethenzamide.Experimental
Ethyl biscoumacetateApocynin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Apocynin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Apocynin.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Apocynin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Apocynin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Apocynin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Apocynin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Apocynin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Feprazone.Experimental
Ferulic acidApocynin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Apocynin.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Apocynin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fludrocortisone.Approved, Investigational
FluindioneApocynin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Apocynin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Apocynin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Flurandrenolide.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Apocynin.Approved, Nutraceutical, Vet Approved
FondaparinuxApocynin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumApocynin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Apocynin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Apocynin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Fosinopril.Approved
GabexateApocynin may increase the anticoagulant activities of Gabexate.Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Apocynin.Approved, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Apocynin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Apocynin is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Apocynin is combined with HE3286.Investigational
HeparinApocynin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Apocynin is combined with Higenamine.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Hydrocortisone.Approved, Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Ibandronate.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Apocynin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Apocynin.Approved, Investigational
IdraparinuxApocynin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apocynin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Apocynin is combined with Imidazole salicylate.Experimental
IndenololApocynin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Apocynin.Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Apocynin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apocynin.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Apocynin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Apocynin is combined with Istaroxime.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Apocynin.Experimental
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Apocynin.Approved
LabetalolApocynin may decrease the antihypertensive activities of Labetalol.Approved
LandiololApocynin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Apocynin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Apocynin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Apocynin.Approved, Investigational
LepirudinApocynin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanApocynin may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololApocynin may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololApocynin may decrease the antihypertensive activities of Levobunolol.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Apocynin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Apocynin.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Apocynin is combined with Lonazolac.Experimental
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Apocynin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Apocynin is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Apocynin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Apocynin.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Apocynin.Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Apocynin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Apocynin is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Medrysone.Approved
MelagatranApocynin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Apocynin is combined with Melengestrol.Vet Approved
MepindololApocynin may decrease the antihypertensive activities of Mepindolol.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Apocynin.Approved, Investigational, Withdrawn
MethylprednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololApocynin may decrease the antihypertensive activities of Metipranolol.Approved
MetoprololApocynin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Apocynin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Apocynin.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Apocynin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Apocynin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apocynin.Approved
NadololApocynin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinApocynin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatApocynin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Apocynin.Approved
NCX 1022The risk or severity of adverse effects can be increased when Apocynin is combined with NCX 1022.Investigational
NebivololApocynin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Nifenazone.Experimental
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apocynin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apocynin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apocynin.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Apocynin is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Apocynin.Vet Approved
OtamixabanApocynin may increase the anticoagulant activities of Otamixaban.Investigational
OxprenololApocynin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apocynin.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Apocynin is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Paramethasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Apocynin is combined with Parthenolide.Approved, Investigational
PenbutololApocynin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateApocynin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateApocynin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Perindopril.Approved
PhenindioneApocynin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonApocynin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apocynin.Approved, Investigational
PindololApocynin may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apocynin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Apocynin is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorApocynin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
Potassium CitrateApocynin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololApocynin may decrease the antihypertensive activities of Practolol.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Apocynin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Apocynin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Pregnenolone.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Apocynin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Apocynin.Approved, Investigational
PropafenoneApocynin may decrease the antihypertensive activities of Propafenone.Approved
PropranololApocynin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Apocynin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Apocynin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Apocynin.Vet Approved
Protein CApocynin may increase the anticoagulant activities of Protein C.Approved
Protein S humanApocynin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeApocynin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Apocynin.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Apocynin is combined with Rescinnamine.Approved
ReviparinApocynin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Apocynin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Risedronate.Approved, Investigational
RivaroxabanApocynin may increase the anticoagulant activities of Rivaroxaban.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Apocynin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Apocynin.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apocynin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Apocynin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Apocynin.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Apocynin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Apocynin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Apocynin is combined with Serrapeptase.Investigational
Sodium CitrateApocynin may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SotalolApocynin may decrease the antihypertensive activities of Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Spirapril.Approved
SpironolactoneApocynin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Apocynin.Investigational
SulodexideApocynin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Apocynin.Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Apocynin is combined with Suxibuzone.Experimental
TacrolimusApocynin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Apocynin.Approved
TalinololApocynin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Apocynin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Apocynin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Apocynin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Apocynin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apocynin.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Apocynin is combined with Tenidap.Experimental
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Apocynin.Vet Approved
TerbutalineApocynin may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Apocynin.Approved
TertatololApocynin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiludronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololApocynin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Apocynin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Apocynin is combined with Tixocortol.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Apocynin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Apocynin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apocynin.Approved
TriamtereneApocynin may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Apocynin is combined with Tribenoside.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Apocynin.Investigational
TroxerutinApocynin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Apocynin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Apocynin.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Apocynin.Approved, Investigational
WarfarinApocynin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranApocynin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Apocynin.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Apocynin.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Apocynin is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Apocynin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apocynin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11380
PubChem Compound
2214
PubChem Substance
347828831
ChemSpider
21106900
ChEBI
2781
ChEMBL
CHEMBL346919
HET
I75
Wikipedia
Apocynin
PDB Entries
3tbc

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBronchial Asthma1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.04 mg/mLALOGPS
logP1.62ALOGPS
logP1.07ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)8.27ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.9 m3·mol-1ChemAxon
Polarizability16.95 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-4900000000-17a85dc123d088c3aa49
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Methoxyphenols / Acetophenones / Phenoxy compounds / Methoxybenzenes / Benzoyl derivatives / Aryl alkyl ketones / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Organic oxides
show 1 more
Substituents
Alkyl-phenylketone / Methoxyphenol / Acetophenone / Phenoxy compound / Methoxybenzene / Aryl alkyl ketone / Anisole / Phenol ether / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid
show 8 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
methyl ketone, aromatic ketone, acetophenones (CHEBI:2781) / Flavans, Flavanols and Leucoanthocyanidins (C11380)

Drug created on October 20, 2016 17:14 / Updated on June 02, 2018 08:40